LM-339

LM-339 is a **preclinical antibody-drug conjugate** being developed by LaNova Medicines for solid tumors, with publicly listed focus indications including **non-small cell lung cancer** and **ovarian cancer**. Publicly available sponsor pipeline materials identify LM-339 as an **ADC**, but the **molecular target, payload, linker, and detailed mechanism of action have not been publicly disclosed**. Based on the disclosed modality, LM-339 is intended to deliver a cytotoxic payload to tumor cells via an antibody-directed targeting strategy, but target-specific biology cannot be assigned with confidence from current public sources.